PATH EX, Inc., a medical device company based in the Texas Medical Center Innovation Factory, has successfully completed a $5 million financing round to advance its breakthrough sepsis treatment technology. The investment, led by IAG Capital Partners with participation from TMC Venture Fund and Fitz Gate Ventures, closed on April 25th, 2025.
The funding will accelerate the development and future commercialization of CycloPE®, a medical device designed to rapidly eradicate bacteria from the bloodstream in patients suffering from sepsis, a life-threatening condition that affects millions worldwide annually.
"We are grateful to have the support of IAG to further our mission of transforming the treatment landscape for sepsis," said Sinead Miller, CEO of PATH EX, Inc. "This funding enables us to take our next steps towards bringing CycloPE® into clinical practice, offering healthcare providers a powerful tool in the fight against this critical condition."
Addressing a Critical Unmet Need
Sepsis remains one of healthcare's most urgent challenges, characterized by the body's extreme response to infection that can rapidly lead to tissue damage, organ failure, and death. Current treatment options are limited primarily to antibiotics and supportive care, with mortality rates remaining unacceptably high.
The CycloPE® device represents a potentially transformative approach by physically removing bacteria from the bloodstream rather than solely relying on pharmaceutical interventions. This mechanical approach could provide a critical new option for patients, particularly as antimicrobial resistance continues to grow as a global health threat.
The financing follows compelling clinical data demonstrating the device's capacity to reduce bacterial load and support key improvements in patient biomarkers. These early results suggest CycloPE® could significantly impact patient outcomes in a condition where rapid intervention is essential.
Strategic Expansion and Regulatory Preparation
The newly secured funds will support several key initiatives, including further product development, additional clinical trials, and expansion of PATH EX's operational capabilities. The company is actively preparing for FDA submission while ensuring the technology meets rigorous safety and regulatory standards.
In conjunction with the financing, PATH EX announced the addition of Jeff Burbank to its Board of Directors. Burbank brings over 30 years of management experience with companies developing, marketing, and manufacturing innovative medical products, providing valuable leadership as the company progresses toward commercialization.
"We believe in the potential of CycloPE® to make a substantial impact on patient care," stated Ehsan Jabbarzadeh, a venture partner at IAG Capital Partners. "Our investment reflects our confidence in PATH EX's innovative technology and the dedicated team behind it."
The Technology Behind CycloPE®
While specific technical details of the CycloPE® device remain proprietary, the technology is designed to physically capture and remove bacteria from the bloodstream. This approach could potentially address limitations of current sepsis treatments, particularly in cases involving drug-resistant pathogens or when patients cannot tolerate aggressive antibiotic regimens.
The device's development comes at a critical time in sepsis care. Despite advances in critical care medicine, sepsis remains a leading cause of in-hospital mortality worldwide. The economic burden is similarly substantial, with treatment costs estimated in the billions annually across healthcare systems.
PATH EX's approach represents a novel direction in sepsis management that could complement existing protocols while potentially reducing treatment time, improving outcomes, and decreasing healthcare costs associated with prolonged intensive care stays.
Looking Toward Clinical Implementation
With this financing secured, PATH EX is positioned to advance CycloPE® through the next stages of development and clinical validation. The company's location within the Texas Medical Center provides strategic advantages, including proximity to leading healthcare institutions for potential clinical partnerships.
Alex Wieseler, Chief Operating Officer at PATH EX, will play a key role in coordinating the company's expanded operations as it moves toward commercialization. The company's experienced team, now strengthened by Burbank's board appointment, combines technical expertise with clinical knowledge essential for navigating the complex medical device development landscape.
For healthcare providers and patients awaiting new options in sepsis care, PATH EX's progress represents a promising development in addressing one of medicine's most persistent challenges. The company's focus on an urgent unmet need, backed by institutional investment and preliminary clinical evidence, positions CycloPE® as a potential breakthrough in the ongoing fight against sepsis.
